(19)
(11) EP 3 207 926 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.07.2021 Bulletin 2021/28

(45) Mention of the grant of the patent:
31.03.2021 Bulletin 2021/13

(21) Application number: 16156194.9

(22) Date of filing: 17.02.2016
(51) International Patent Classification (IPC): 
A61K 31/201(2006.01)
A61K 31/4184(2006.01)
A61K 31/496(2006.01)
G01N 33/68(2006.01)
A61K 31/336(2006.01)
A61K 31/445(2006.01)
A61P 25/02(2006.01)

(54)

OXIDIZED LIPIDS IN THE TREATMENT OF CHRONIC OR NEUROPATHIC PAIN

OXIDIERTE LIPIDE ZUR BEHANDLUNG BEI CHRONISCHEN ODER NEUROPATHISCHEN SCHMERZEN

LIPIDES OXYDÉS DANS LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE CHRONIQUE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
23.08.2017 Bulletin 2017/34

(73) Proprietors:
  • Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    80686 München (DE)
  • Johann-Wolfgang-Goethe-Universität Frankfurt am Main
    60323 Frankfurt am Main (DE)

(72) Inventors:
  • SISSIGNANO, Marco
    60385 Frankfurt (DE)
  • GEISSLINGER, Gerd
    65812 Bad Soden (DE)
  • PARNHAM, Michael John
    65812 Bad Soden/Ts (DE)

(74) Representative: Altmann Stößel Dick Patentanwälte PartG mbB 
Dudenstrasse 46
68167 Mannheim
68167 Mannheim (DE)


(56) References cited: : 
EP-A1- 2 642 293
WO-A1-2016/024015
WO-A1-2009/062073
WO-A2-2010/062900
   
  • B. INCEOGLU ET AL: "Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 28, 25 June 2012 (2012-06-25), pages 11390-11395, XP055291837, US ISSN: 0027-8424, DOI: 10.1073/pnas.1208708109
  • SHUNJI KUNORI ET AL: "A novel role of prostaglandin E2 in neuropathic pain", GLIA, vol. 59, no. 2, 1 February 2011 (2011-02-01), pages 208-218, XP055291731, US ISSN: 0894-1491, DOI: 10.1002/glia.21090
  • RAMSDEN CHRISTOPHER E ET AL: "Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: A randomized trial", PAIN, vol. 154, no. 11, 1 November 2013 (2013-11-01), pages 2441-2451, XP028744054, ISSN: 0304-3959, DOI: 10.1016/J.PAIN.2013.07.028
  • POULSEN J N ET AL: "IBUDILAST AND SKF MODULATE CISPLATIN-EVOKED PGE2 RELEASE FROM ISOLATED TRIGEMINAL SATELLITE GLIAL CELLS", GLIA, vol. 61, no. Suppl. 1, July 2013 (2013-07) , page S109, XP002760364, & 11TH EUROPEAN MEETING ON GLIAL CELL FUNCTION IN HEALTH AND DISEASE; BERLIN, GERMANY; JULY 03 -06, 2013
  • ANU UPADHYAY: "Reflex Sympathetic Dystrophy-Like Syndrome, Possibly Caused By Aripiprazole, in an Adolescent Patient", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, vol. 24, no. 7, 1 September 2014 (2014-09-01), pages 414-415, XP55220115, US ISSN: 1044-5463, DOI: 10.1089/cap.2014.0032
  • Amol M. Patwardhan ET AL: "Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents", Journal of Clinical Investigation, vol. 120, no. 5, 3 May 2010 (2010-05-03), pages 1617-1626, XP55042034, ISSN: 0021-9738, DOI: 10.1172/JCI41678
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).